Companies: 10,795·Total market cap: $144.5T
Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc.

AVTENASDAQHealthcare
$2.68
+$0.00(+0.00%)
Market Cap$77679800
P/E Ratio
52W High$884.975
52W Low$2.6296
Overview

Aerovate Therapeutics, Inc. (AVTE) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · AVTE · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-3754.64avte eps ttm · avte earnings per shareEarnings history
PE Ratio (TTM)avte pe ratio ttm · avte price to earningsPE Ratio deep dive
Revenue (TTM)0.00avte revenue ttm · avte annual revenueFull revenue history
Dividend Yield0.00%does avte pay dividends · avte dividend yieldDividend history
Shares Outstanding31.4Mavte shares outstanding · avte floatShares outstanding history
Next EarningsTBAavte earnings date · avte next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
aerovate therapeutics, inc. revenue · avte revenue 2025
FY 2025Net Income-$127.4M▼ 82.99% YoY
202320242025
aerovate therapeutics, inc. net income · avte profit 2025
FY 2025EPS$-3193.30▼ 130772.95% YoY
202320242025
avte eps · aerovate therapeutics, inc. earnings per share 2025
TTM:Revenue: $0.00Net Income: -$165.3MEPS: $-3754.64View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Hold8 analystsis avte a buy · avte analyst rating
Strong Buy
0
Buy
2
Hold
6
Sell
0
Strong Sell
0
12-Month Price Target
$2.00Low
$2.68Current
$13.00Avg Target385.07% upside
$35.00High
avte price target · avte 12 month forecast

Total: 8 · Buy rate: 25.0%

The AVTE analyst consensus is Hold, based on ratings from 8 Wall Street analysts over the past 3 months. The average 12-month price target is $13.00, representing +385.07% upside from the current price of $2.68.

Stock Performance

Full History
1D+0.00%
1W+0.00%
1M-97.14%
3M-96.85%
YTD-97.15%
1Y-99.52%
5Y-99.66%

About Aerovate Therapeutics, Inc.

CEOTimothy P. Noyes
IPO DateJun 30, 2021
Employees4
CountryUS

Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on innovating therapies to enhance the well-being of patients afflicted with rare cardiopulmonary illnesses across …

what is aerovate therapeutics, inc. · avte stock overview · aerovate therapeutics, inc. company profile · who is aerovate therapeutics, inc. ceo · avte NASDAQ · aerovate therapeutics, inc. headquarters · aerovate therapeutics, inc. business segments

About Stock Overview & Key Data

Aerovate Therapeutics, Inc. (AVTE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 30, 2021. As of the latest trading session, AVTE stock price is $2.68, with a market capitalization of $77.7M. The stock has returned -99.52% over the past 12 months and -97.15% year-to-date.

According to 8 Wall Street analysts, the consensus rating for Aerovate Therapeutics, Inc. stock is Hold, with an average 12-month price target of $13.00. In fiscal year 2025, Aerovate Therapeutics, Inc. reported revenue of — and net income of -$127.4M. For detailed data — including Aerovate Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Aerovate Therapeutics, Inc. (AVTE) stock price is $2.68. The stock is traded on NASDAQ under the ticker symbol AVTE. The 52-week range is $2.63 – $884.98.

AVTE stock priceAVTE quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice